肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
现在就能报名的（招募中）排在最前，共 0 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
Claudin18.2 and the PD-1/PD-L1 axis in gastric cancer: mechanistic insights and implications for combination immunotherapy.
本综述提示，Claudin18.2 在胃癌中可能作为免疫功能障碍的关键调节因子，而非免疫排斥因子，为将 Claudin18.2 靶向治疗与免疫检查点抑制相联合的组合策略提供了潜在的生物学依据。
Claudin18.2-positive gastric cancer-specific changes in neoadjuvant chemotherapy-driven immunosuppressive tumor microenvironment.
我们的研究结果表明，化疗可驱动 CLDN18.2 阳性 GC 特有的免疫抑制性 TME 改变。
The Landscape of Clinical Trials for Claudin18.2-Positive Gastric Cancer.
CLDN18.2 已成为胃癌靶向治疗的重要新靶点。
ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric
Advances in Immunotherapy and Targeted Therapy for Gastric Cancer: A Comprehensive Review.
MEMBER ACCOUNT
登录成功会直接打开下一页。
